Syqe Medical has created the world’s first precision medical marijuana inhaler using 3D printing technology. The device is also WI fi enabled and can work in conjunction with mobile devices.
As the use of medical marijuana enters the mainstream around the world, many a company is looking to find ways to make money by offering people new devices that make it easier to consume the drug. One such device is an inhaler.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
The comedian Sarah Silverman recently shocked people when she was shown on television smoking pot with an inhaler while on her way into the Emmy Awards ceremonies last month in Los Angeles. Medical marijuana is legal in California and she has a prescription.
Some people have even taken to putting marijuana into the new electronic cigarettes so that they can inhale it as vapor.
The Syqe Inhaler is a pocket-sized metered-dose cannabis inhaler. It utilizes selective 100 microgram dosing precision, real time thermal & flow controllers, lung interfacing and wireless connectivity. The company boasts that the device will allow patients to reach the, “coveted optimum balance between symptom relief and psychoactivity, regaining their quality of life.”
The platform is comprised of proprietary raw drug Structural-Modification methods, uniquely identified preloaded cartridges and a linked clinical database serving physicians, researchers and healthcare entities. The Syqe Inhaler will be available for home use in 2015.
The Syqe Inhaler Exo is a hospital version metered-dose cannabis inhaler for professional healthcare use, featuring a caregiver interface, which will be available for hospital use by the end of 2014.
The Israeli company Syqe medical states that it aims to transform cannabis and other psychoactive botanicals into mainstream medical drugs. It declares its vision to be to decentralize drug development and streamline its clinical testing in a 21st century fashion.
To achieve these goals the company has been absorbing cutting-edge technologies for nearly 4 years and employs a multi-disciplinary team of electronic engineers, mechanical engineers, industrial designers, chemists, biologists, physicians and Pharmacologists.
Syqe Medical founder and CEO Perry Davidson told the Wall Street Journal, “We are directly manipulating the human psyche in a very precise manner. A physician could prescribe a custom-tailored, individualized treatment for that patient, and not have a hit or a miss, but a very close hit on the accurate dosing that the patient required.”